ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 13 (4) 1121-1133    DOI: 10.1677/erc.1.01257
Copyright © 2006 by the Society for Endocrinology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuske, B.
Right arrow Articles by Cameron, D. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuske, B.
Right arrow Articles by Cameron, D. A

Endocrine therapy resistance can be associated with high estrogen receptor {alpha} (ER{alpha}) expression and reduced ER{alpha} phosphorylation in breast cancer models

Barbara Kuske1, Catherine Naughton1, Kate Moore1, Kenneth G MacLeod1, William R Miller1, Robert Clarke2, Simon P Langdon1 and David A Cameron1

1 CRUK Cancer Research Centre and Academic Breast Unit, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK,
2 Department of Oncology, Georgetown University, Washington, District of Columbia, USA

(Requests for offprints should be addressed to S P Langdon; Email: simon.langdon{at}cancer.org.uk)

B Kuske and C Naughton contributed equally to this work.

Hormone-dependent estrogen receptor (ER)-positive breast cancer cells may adapt to low estrogen environments such as produced by aromatase inhibitors. In many instances, cells become insensitive to the effects of estrogen but may still retain dependence on ER. We have investigated the expression, function, and activation of ER{alpha} in two endocrine-resistant MCF-7 models to identify mechanisms that could contribute to resistance. While MCF-7/LCC1 cells are partially estrogen dependent, MCF-7/LCC9 cells are fully estrogen insensitive and fulvestrant and tamoxifen resistant. In both MCF-7/LCC1 and MCF-7/LCC9 cell lines, high expression of ER{alpha} was associated with enhanced binding to the trefoil factor 1 (TFF1) promoter in the absence of estrogen and increased transcription of TFF1 and progesterone receptor. In contrast to the observations derived from hypersensitive and supersensitive models, these cells were truly estrogen independent; nevertheless, removal of ER{alpha} by siRNA, or fulvestrant, a specific ER downregulator, inhibited growth indicating dependence on ER{alpha}. In the absence of estrogen, neither ER{alpha} Ser118 nor Ser167 were phosphorylated as frequently found in other ligand-independent cell line models. Addition of estrogen activated ER{alpha} Ser118 in MCF-7 and LCC1 cells but not in LCC9 cells. We suggest that the estrogen-independent growth within these cell lines is accounted for by high levels of ER{alpha} expression driving transcription and full estrogen independence explained by lack of ER{alpha} activation through Ser118.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Masri, S. Phung, X. Wang, X. Wu, Y.-C. Yuan, L. Wagman, and S. Chen
Genome-Wide Analysis of Aromatase Inhibitor-Resistant, Tamoxifen-Resistant, and Long-Term Estrogen-Deprived Cells Reveals a Role for Estrogen Receptor
Cancer Res., June 15, 2008; 68(12): 4910 - 4918.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
C. Naughton, K. MacLeod, B. Kuske, R. Clarke, D. A. Cameron, and S. P. Langdon
Progressive Loss of Estrogen Receptor {alpha} Cofactor Recruitment in Endocrine Resistance
Mol. Endocrinol., November 1, 2007; 21(11): 2615 - 2626.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Endocrinology.